Pharmaceutical

MSD’s Keytruda wins expanded FDA combo approval in cervical cancer

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

Jan 15, 2024 - 18:00
MSD’s Keytruda wins expanded FDA combo approval in cervical cancer
MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.
Read the original article

Tags:

Previous Article

Amgen showcases exciting potential in the obesity space at JPM24

Next Article

Basilea buys Spexis’ preclinical antibiotics programme for $2.3m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos...

May 19, 2023

Sage Therapeutics fires 40% of staff after FDA rejected MDD bid

Sage Therapeutics fires 40% of staff after FDA rejected...

Sep 1, 2023

STAT+: Not-for-profit CommonSpirit Health paid its CEO $35 million in 2021

STAT+: Not-for-profit CommonSpirit Health paid its CEO ...

Aug 15, 2023